Tb : Recent recommendation. Dr.Ketan Shah
|
|
|
- Flora Price
- 5 years ago
- Views:
Transcription
1 Tb : Recent recommendation Dr.Ketan Shah
2 Tbc : Clinician If you think It is easy to diagnose : u r not good clinician It is difficult to diagnose :U r not alone doctor to think this 6/22/2015 Ketan Shah IAP surat 2
3 6/22/2015 5yrs/Female- Vibhuti FTT Poor appetite Wt < 25 th percentile O/E ; no lymph-adenopathy No organo-megaly Repeatedly parents insist for FTT Pediatrician has not kept Growth chart Frustrated Pediatrician asked for MT Ketan Shah IAP surat 3
4 Look at the lab request 6/22/2015 Ketan Shah IAP surat 4
5 MT : most trusted test????? Report 10 mm of indurations and 15 mm of erythema MT strength 10Tu/0.1 ml 6/22/2015 Ketan Shah IAP surat 5
6 Fallacies in case History of Wt loss Many reasons Actual 5% of last 3 months Fussy eater Other reasons No growth chart TST /MT fallacies 6/22/2015 Ketan Shah IAP surat 6
7 TST/MT 5 TU PPD-S= 2 TU PPD RT 23 with Tween 80 Available at Gayatri chemicals,surat 6/22/2015 Ketan Shah IAP surat 7
8 TST (MT)FAQs TST >20 mm Suggest Just infection not sever disease Ulceration = severe disease? What if comes after 7 days? read BCG test more useful? No Repeat TST after completion of ATT? No Reactivation or re-infection what happens to TST? No correlation 6/22/2015 Ketan Shah IAP surat 8
9 TST MT : most un--trusted and asked test. Mantoux test suggest infection with MTB not disease, Isolated positive test does not merit treatment 6/22/2015 Ketan Shah IAP surat 9
10 There is H/o Contact with TB in family MT done 10mm report (2TU/0.1 mm )????? Do you start ATT Investigate /define and start /prophylaxis 6/22/2015 Ketan Shah IAP surat 10
11 Contact tracing Due importance Go for microbiological diagnosis Insist for the same Investigate for disease and if no disease found start prophylaxis INH 10 mg/kg/day 6 months 6/22/2015 Ketan Shah IAP surat 11
12 Six months old child coming with lymph node in axilla. Has received BCG at birth FNAC shows mycobacteria positive in microscopy. AKT????????? ( rule out disseminated BCG Tb ) NO 6/22/2015 Ketan Shah IAP surat 12
13 Nistha 12 yrs/f H/o chronic cough Productive cough f/h/o open case of Koch s 6/22/2015 Ketan Shah IAP surat 13
14 X-ray chest 6/22/2015 Ketan Shah IAP surat 14
15 Will you ask for sputum? If yes ; how?, What? How many days? What is recent recommendation? Gastric aspirate ; good option try 6/22/2015 Ketan Shah IAP surat 15
16 Bronchoscopy and BAL If available should be tried 6/22/2015 Ketan Shah IAP surat 16
17 6/22/2015 Ketan Shah IAP surat 17
18 6/22/2015 Ketan Shah IAP surat 18
19 What you will ask in sputum? Miscroscopy Direct microscopy by staining Fluorescent microscopy more preferred CBNAAT (genexpert/rif) Culture :liquid culture :MGIT Solid culture :LJ media 6/22/2015 Ketan Shah IAP surat 19
20 Parents want urgent reports Asked for Ab detection (serology ) Ag detection Interferon gamma release tests (IGRA) 6/22/2015 Ketan Shah IAP surat 20
21 Interferon gamma assay IGRA Elispot-Tb Quantiferon Tb gold Just indicates child has latent Tb infection Does not indicate disease Limitations Not routinely recommended 6/22/2015 Ketan Shah IAP surat 21
22 Summary of available diagnostic tests for Tb Smear Sputum /gastric aspirate Culture MGIT LJ CBNAAT Radiology TST Be ware of false results Indicates infection but not disease 6/22/2015 Ketan Shah IAP surat 22
23 8yrs /M H/o acute onset of fever Chest pain O/E : suggestive of pneumonia and mild effusion 6/22/2015 Ketan Shah IAP surat 23
24 1 st x-ray 6/22/2015 Ketan Shah IAP surat 24
25 Effusion increased 6/22/2015 Ketan Shah IAP surat 25
26 Repeat x-ray 6/22/2015 Ketan Shah IAP surat 26
27 Does TST helps? Does CBC, ESR helps? Plural fluid study Exudative :p : >3 gm %,not pus Straw color Lymphocytic count 50-to-few thousands ADA No role CB-NAAT /ZN staining Plural biopsy Search for Tb at other site Gastric aspirate /sputum if available 6/22/2015 Ketan Shah IAP surat 27
28 Lymph node Tb >2 cm Trial of AB (not linezolid, quinolones ) No response go for FNAC FNAC Smear Histo-pathology MGIT CBNAAT 6/22/2015 Ketan Shah IAP surat 28
29 Search for evidance at other site TST +ve but biopsy negative do not start ATT USG gland : central hypo-echogenicity Necrotic gland 6/22/2015 Ketan Shah IAP surat 29
30 Ab Tb Necrotic gland Other constitutional s/s Think of Tb r/o IBD (Crohn s etc ) Send any available material for CB-NAAT 6/22/2015 Ketan Shah IAP surat 30
31 Treatment Intensive phase Continuation phase Purpose 6/22/2015 Ketan Shah IAP surat 31
32 Ethambutol safe Good drug for neuro Tb than SM 6/22/2015 Ketan Shah IAP surat 32
33 In HIV + ve cases intermittent regime not useful Daily Observed therapy ( DOT daily ) is recommended HIV ve : Intermittent /daily recommended 6/22/2015 Ketan Shah IAP surat 33
34 India is in high INH resistance country Huge Impact on treatment 6/22/2015 Ketan Shah IAP surat 34
35 IAP-RNTCP 2015 Cat of treatment Type of Pt Regimens New (old cat 1) Retreatment (old Cat 2 ) New Bacterilogically confirmed Tb Clinically diagnosed Tb Extra pulmonary Bact confirmed retreatment Microbiologically +failure Microbiologically +ve defaulter Other 2HRZE + 4HRE 2HRZE + 1HRZE +5HRE Others : Sputum-ve /extra pulmonary recurrence 6/22/2015 Ketan Shah IAP surat 35
36 Note changes in doses 3/week Daily R 15 ( 12-17) (Max 600) H 15 (12-17) 10 ( max 300 ) Z 35 (30-40) (max 1500 ) E 30 (25-30) (max 2000 ) S (max 1 gm ) 6/22/2015 Ketan Shah IAP surat 36
37 FDC Recommended Ratio 1:1.5:3 ( 10:15 ;30 ) Not 1:2 H :50, R : 75,Z : 150 ideal Non of the formulation has this combination 6/22/2015 Ketan Shah IAP surat 37
38 Role of steroid /adjuvant drugs In CNS Tb for 4 weeks than taper In pericardial effusion Tb : yes In plural effusion : if bilateral /massive yes /not must Pyridoxine ; in pregnancy and sever malnutrition Not routinely 6/22/2015 Ketan Shah IAP surat 38
39 Thank you BUT STILL MORE TO LEARN 6/22/2015 Ketan Shah IAP surat 39
40 History Vicky M/9 yrs Dec admitted for PUO All reports negative,x-ray normal? Enteric fever Responded to ceftriaxone 6/22/2015 Ketan Shah IAP surat 40
41 HISTORY After 20 days fever reappeared Toxic child admitted After 4 days drowsy X-ray shows Miliary Tb CT brain shows localised Tuberculoma 6/22/2015 Ketan Shah IAP surat 41
42 1st X-ray Jan 2006 Miliary- snow-storm pattern 6/22/2015 Ketan Shah IAP surat 42
43 Treatment AKT Steroid Anticonvulsant Better for 2 months Steroid tapered after 2 months 6/22/2015 Ketan Shah IAP surat 43
44 Convulsion S/S of RICT Repeat CT shows increased lesions Bilateral 6/22/2015 Ketan Shah IAP surat 44
45 1st CT scan Left parietal Granuloma 6/22/2015 Ketan Shah IAP surat 45
46 New lesions in CT Right side,, After 3 months of AKT, X-ray normal ( march 2006) 6/22/2015 Ketan Shah IAP surat 46
47 New lesions in CT 6/22/2015 Ketan Shah IAP surat 47
48 What happened? Why so? 6/22/2015 Ketan Shah IAP surat 48
49 Therapeutic paradox Immune phenomena Resistant bacteria? How to differentiate What is the approach? 6/22/2015 Ketan Shah IAP surat 49
50 Trial of AKT Is IT a good clinical judgment??? 6/22/2015 Ketan Shah IAP surat 50
51 Abdominal pain 12 yrs /F R A P (recurrent abdominal pain ) Good growth No other findings USG shows Mesenteric LN 1-2 cm in size MT : 0 mm, CBC: Normal, ESR:25 mm AKT started????????/comment.. 6/22/2015 Ketan Shah IAP surat 51
52 Rekha, 8 years girl, Resident of Delhi H/o: Swelling in neck for 5 months Occasional vomiting and low grade fever, no cough, distress No history of definite contact with Tb patient Physical Examination Weight 14 kg, Height 110 Cms HR 100/ min, RR 28 /min Bilateral cervical nodes, multiple, matted 3-4 Cms in size Discharging sinus over sternum Rest WNL 6/22/2015 Ketan Shah IAP surat 52
53 Investigations Mantoux test positive: 25 mm CXR: Superior mediastinum wide, no lung parenchymal lesions Hb; 10, TLC 10200, P 55, L42, E 3, ESR 23 mm PS: Normal no atypical cells, Platelets adequate Family survey for Tb WNL FNAC from node suggest: Granuloma, Necrosis, AFB positive 6/22/2015 Ketan Shah IAP surat 53
54 Q 1: What should be the treatment for this patient? 6/22/2015 Ketan Shah IAP surat 54
55 Treatment received Child was started on 2 HRZE 4 HR No improvement in size of the node and discharging sinus No weight gain Developed daily low grade pyrexia and poor appetite after 2 months of treatment 6/22/2015 Ketan Shah IAP surat 55
56 Q: How this patient should be managed now? 6/22/2015 Ketan Shah IAP surat 56
57 Course of illness Screened for other infections including UTI, and intensive phase extended for another one month. ( RNTCP ) No significant improvement in symptoms after extended one month of intensive phase AFB positive from the discharging sinus. 6/22/2015 Ketan Shah IAP surat 57
58 Gene expert study shows resistance pattern 6/22/2015 Ketan Shah IAP surat 58
59 Q: What should be the management now? 6/22/2015 Ketan Shah IAP surat 59
60 Course of illness Culture for AFB taken Child was started on cat 2 regimen: 2 SHRZE, 1 HRZE, 5 HRE No weight gain, continue to have low grade fever, no decrease in size of nodes Culture available after 2 months and M Tb resistant to HR 6/22/2015 Ketan Shah IAP surat 60
61 Q: How to manage this patient now? 6/22/2015 Ketan Shah IAP surat 61
62 Course of illness Admitted in hospital, Started on Ethionamide, Kanamycin, ofloxacin and pyrazinamide Monitored for side effects in hospital by doing LFTs twice a week and discharged after two weeks 6/22/2015 Ketan Shah IAP surat 62
63 Follow up In TB clinic: Fever and discharge from sinus responded in 2 weeks, appetite improved. No AFB from sinus discharge at 2, 3 months At 6 months: Lymphnodes < 1 Cm, sinus healed completely, kanamycin stopped, rest of medications continued At 18 months of treatment: weighs 20 Kg, no systemic manifestations: ATT stopped At 24 months asymptomatic 6/22/2015 Ketan Shah IAP surat 63
64 Step 1 Begin with any First line agents to Which the isolate is Susceptible Use any available First-line drugs PLUS One of these Fluoroquinolones PLUS One of these Injectable agents Add a Fluoroquinolone And an injectable Drug based on susceptibilities Pyrazinamide Ethambutol Ofloxacin Levofloxacin Moxifloxacin Amikacin Capreomycin Streptomycin Kanamycin 64 6/22/2015 Ketan Shah IAP surat 64 BS
65 Step 1 Begin with any First line agents to Which the isolate is Susceptible Use any available First-line drugs PLUS One of these Fluoroquinolones PLUS One of these Injectable agents Add a Fluoroquinolone And an injectable Drug based on susceptibilities Pyrazinamide Ethambutol Levofloxacin Moxifloxacin Amikacin Capreomycin Streptomycin Kanamycin Step 2 Add 2 nd line drugs until you have 4-6 drugs to which isolate is susceptible (which have not been used previously) Pick one or more of these Oral second line drugs Cycloserine Ethionamide PAS 65 6/22/2015 Ketan Shah IAP surat 65
66 Step 1 Begin with any First line agents to Which the isolate is Susceptible Use any available First-line drugs PLUS One of these Fluoroquinolones PLUS One of these Injectable agents Add a Fluoroquinolone And an injectable Drug based on susceptibilities Pyrazinamide Ethambutol Levofloxacin Moxifloxacin Amikacin Capreomycin Streptomycin Kanamycin Step 2 Add 2 nd line drugs until you have 4-6 drugs to which isolate is susceptible (which have not been used previously) Step 3 Pick one or more of these Oral second line drugs Cycloserine Ethionamide PAS Consider use of these 66 If there are not 4-6 drugs available consider 3 rd line in consult with MDRTB experts Third line drugs Imipenem Linezolid Macrolides Amoxicillin/Clavulanate 6/22/2015 Ketan Shah IAP surat 66 BS
67 What is status of chemoprophylaxis for contacts of MDR TB? 6/22/2015 Ketan Shah IAP surat 67
68 Causes of Drug resistance Essentially drug resistance is a man made phenomenon Providers/Programmes: Inadequate regimens Drugs: Inadequate supply Poor quality Patients: Inadequate drug intake 6/22/2015 Ketan Shah IAP surat 68
69 What is X DR TB? Extensive drug-resistant TB (XDR-TB) is defined as a multidrug-resistant TB strain which is also resistant to Quinolones and one of the injectable XDR-TB is related to the poor management of MDR-TB cases (which in turn is the consequence of sub optimally managed susceptible TB). Countries with high incidence of MDR-TB are at high risk for emergence of XDR-TB. 6/22/2015 Ketan Shah IAP surat 69
70 Resistant tuberculosis: Drugs used and their doses Drugs Dose per kg per day Ethionamide (PO) Cycloserine (PO) Ciprofoxacin (PO) Ofloxacin 10 (PO) Kanmycin 15 (IM) Amikacin 15 (IM) 6/22/2015 Ketan Shah IAP surat 70
71 Management of MDR TB Resistance to Drugs in intensive phase Minimum duration in months Drugs in continuation phase Duration in months H and R Aminoglycosides Ethionamide Ethionamide Ofloxacin PZA 3 Ethambutol Ofloxacin Ethambutol 3 3 Cycloserine/ PAS Cycloserine/ PAS 3 HSR and E Aminoglycosides Ethionamide Ethionamide Ofloxacin PZA Ofloxacin 3 3 Cycloserine/ PAS Cycloserine/ PAS 3 6/22/2015 Ketan Shah IAP surat 71
72 Suraj, 3 years boy, resident of UP Known HIV positive for past 5 months on Three ART (lamivudine, nevirapine and stavudine) P/c: fever, cough, breathing difficulty: 15 days Treated with oral antibiotics (Augmentin) No improvement Mother died of HIV illness 2 months ago and had severe emaciation Father is HIV positive but asymptomatic 6/22/2015 Ketan Shah IAP surat 72
73 X-ray /CT and BAL proved tuberculosis of lungs 6/22/2015 Ketan Shah IAP surat 73
74 Q1: How to manage this patient? Shall we give ATT alone or ATT and ART? If both than what modifications in ART? 6/22/2015 Ketan Shah IAP surat 74
75 Considerations for the choice of first-line ARV regimens in children receiving rifampicin containing TB treatment The co-management of TB and HIV, and the treatment of HIV infection, is complicated by drug interactions, particularly rifampicin and the NNRTI and PI These drugs have similar routes of metabolism and coadministration results in subtherapeutic antiretroviral drug levels 6/22/2015 Ketan Shah IAP surat 75
76 HIV TB co-infection In HIV-infected children with TB disease, the initiation of TB treatment is the priority. Optimal timing for the initiation of ART during TB treatment is not known Decision on when to start ART after starting TB treatment is balance of following child s age pill burden potential drug interactions overlapping toxicities and possible immune reconstitution syndrome versus the risk of further progression of immune suppression with its associated increase in mortality and morbidity. 6/22/2015 Ketan Shah IAP surat 76
77 Clues to Tbc Red elevated nodular lesion on shin border??? Erythema nodosa 6/22/2015 Ketan Shah IAP surat 77
78 Red eye with phlycten.phlyctencular conjunctivitis 6/22/2015 Ketan Shah IAP surat 78
79 Sorry to confuse u. 6/22/2015 Ketan Shah IAP surat 79
Clinical Management : DR-TB
Clinical Management : DR-TB Charoen Chuchottaworn MD., Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH. Tuberculosis Classification Drug susceptible TB
TB Grand Rounds. MDR-TB: Management of Adverse Drug Reactions. Reynard J. McDonald, M.D. September 18, Patient History
TB Grand Rounds MDR-TB: Management of Adverse Drug Reactions Reynard J. McDonald, M.D. September 18, 2007 Patient History This 30 y/o H/M was born in Ecuador and immigrated to the US in 2001 On 11-22-05
THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION
1 THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION Dr. Norbert Ndjeka MD, DHSM (Wits), MMed(Fam Med) (MED), Dip HIV Man (SA) Director Drug-Resistant TB, TB and HIV National Department of Health
TB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD
TB Intensive Houston, Texas November 10-12, 12 2009 Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD November 12, 2009 Multi-Drug Resistant (MDR) TB Updates November 12, 2009 Barbara J. Seaworth Professor
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S. Barbara J. Seaworth, M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director, Heartland
TB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Drug Resistant TB Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received research funding from
Dr Sharanjit Dhoot. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Sharanjit Dhoot Chelsea and Westminster Hospital, London 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual
Treatment of Drug Resistant TB
Treatment of Drug Resistant TB Diana M. Nilsen RN, MD Bureau of TB Control New York City Department of Health & Mental Hygiene Objectives Definition of other drug resistant (ODR), multiple drug resistant
Multidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership
Multidrug-resistant Tuberculosis Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership Disclosures World Health Organization Chair, Global GLC Otsuka Chair, Data Monitoring
Summary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing - PRELIMINARY -
Summary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing PRELIMINARY 4 th Annual GLI meeting 17 April 2012 Fuad Mirzayev Laboratories, Diagnostics and Drug Resistance unit, Stop
Challenges to treat MDR TB
Challenges to treat MDR TB Manfred Danilovits Tartu University Hospital, Estonian NTP Program 2nd European Advanced Course in Clinical Tuberculosis 22-24 September 2014, Amsterdam MDR-TB control; WHO Europe,
DR-TB PATIENT IDENTITY CARD
Ministry of Health Community Development Gender Elderly and Children National Tuberculosis and Leprosy Programme DR-TB 02 DR-TB Treatment Unit: DR-TB PATIENT IDENTITY CARD DR-TB Reg. Number: Date of registration:
Case Presentations: Non Responding TB Dr. Manoj Yadav
Case Presentations: Non Responding TB Dr. Manoj Yadav mbbs, dtcd, dnb (resp. dis.) Consultant Pulmonologist Kailash Hospital, Kailash Complex Near Mahadev Temple, Productivity Road Vadodara 390007 :: Phone:
Drug resistant TB: The role of the laboratory
Drug resistant TB: The role of the laboratory 26 Oct 2012 Andrew Whitelaw NHSLS / UCT TB lab functions: Outline Resistance testing Genotypic Phenotypic Which tests are done when, and why Reporting of
Multi-Drug and Extensively Drug Resistant Tuberculosis
Multi-Drug and Extensively Drug Resistant Tuberculosis Gwen A. Huitt, M.D., M.S. Professor, Department of Medicine Director, Adult Infectious Disease Care Unit National Jewish Health Disclosures None Tuberculosis
MDR/XDR TB. Barbara Seaworth, MD, FIDSA, FACP October 27, TB Intensive October 24 27, 2017 San Antonio, TX
MDR/XDR TB Barbara Seaworth, MD, FIDSA, FACP October 27, 2017 TB Intensive October 24 27, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Barbara Seaworth, MD, FIDSA, FACP, has the following disclosures
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,
Clinical Manifestations and Treatment of Plague Dr. Jacky Chan. Associate Consultant Infectious Disease Centre, PMH
Clinical Manifestations and Treatment of Plague Dr. Jacky Chan Associate Consultant Infectious Disease Centre, PMH Update of plague outbreak situation in Madagascar A large outbreak since 1 Aug 2017 As
Subacute Adenitis. Ann M. Loeffler, MD
Subacute Adenitis Ann M. Loeffler, MD Lymphadenitis Swelling and hyperplasia of sinusoidal lining cells Infiltration of leukocytes +/- abscess formation Granulomatous or non-granulomatous Pyogenic adenitis
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
Case 1 and Case 2. Case 1 3/23/2016
Case 1 and Deidra D. Parrish, MD, MPH&TM Nashville Metro Public Health Dept TB Symposium March 30, 2016 Case 1 27 yo Indian woman came to the US to join her husband three months prior to clinic visit.
Drug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
Practical. Walk through New Survival Guide
Many faces of TB: Drug resistant it ttbs Survival lgid Guide v3 P B L Ch G Sh t L T P. Barry, L. Chen, G. Schecter, L. True Curry International TB Center/CTCA April 20, 2016 Real case Practical Walk through
Outlines. Introduction Prevalence Resistance Clinical presentation Diagnosis Management Prevention Case presentation Achievements
Amal Meas Al-Anizi, PharmD Candidate KSU, Infectious Disease Rotation 2014 Outlines Introduction Prevalence Resistance Clinical presentation Diagnosis Management Prevention Case presentation Achievements
GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
Multidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool)
Multidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool) DOTS + and LTBI New drugs for TB and the challenge of resistance talk plan 1. Epidemiology 2. Treatment 3. The MDRTB
Management of MDR and XDR TB Prof. Martin Boeree
Management of MDR and XDR TB 1, MD, PhD Associate Professor Consultant Respiratory Medicine Department of Lung Diseases Radboud University Nijmegen Medical Centre TB Referral Hospital Dekkerswald Nijmegen,
MDR-TB drugs per WHO guidelines
New antituberculous agents for drug-resistant resistant TB Symposium Belgian Society of Infectiology and Clinical Microbiology November 9 Jens Van Roey, MD - Tibotec Definitions MDR-TB multidrug resistance
Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance
Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance 22nd Congress of the EAHP "Hospital pharmacists catalysts for change", 22-24 March 2017, Cannes Disclosure
TB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 MDR/XDR TB Barbara J. Seaworth, MD October 16, 2013 Barbara J. Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial
Exploring Novel Approaches to Shared TB Laboratory Services: California-Wisconsin Shared Services Pilot Study
Exploring Novel Approaches to Shared TB Laboratory Services: California-Wisconsin Shared Services Pilot Study Julie Tans-Kersten, MS, BS-MT (ASCP) Tuberculosis Laboratory Program Coordinator Wisconsin
MDR TB AND CASE STUDIES
MDR TB AND CASE STUDIES Chris Keh, MD Director, TB Prevention and Control Program, SFDPH HS Assistant Clinical Professor, Infectious Diseases, UCSF Seattle, CITC Clinical Intensive June 15, 2018 Slide
MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2
1 MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2 1 India has the highest TB burden in the world 3 4 2 5 M. tuberculosis Resistance
Rational use of antibiotic in upper respiratory tract infection (URI) and community acquired pneumonia รศ.จามร ธ รตก ลพ ศาล 23 พฤษภาคม 2550
Rational use of antibiotic in upper respiratory tract infection (URI) and community acquired pneumonia รศ.จามร ธ รตก ลพ ศาล 23 พฤษภาคม 2550 Sinusitis Upper respiratory tract infections (URI) Common cold
Effects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB)
Effects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB) Session: Fanning the Flames of HIV and TB Cointeraction SA AIDS Conference-Durban ICC 13-15 June 2017
XDR TB: The Laboratory s Dilemma vs The Clinician s Dilemma
XD TB: The Laboratory s Dilemma vs The Clinician s Dilemma Barbara J. Seaworth, MD, FIDSA, FACP, Heartland National TB Center, San Antonio, TX Kenneth Jost, Jr., M(ASCP) Laboratory Services Section, Texas
MGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience
MGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience Dr Johan Van Wyk MB.Ch.B, M.Med (Clin Path) Clinical Pathologist ibhayi Region, Eastern Cape GWYNETH PALTROW SHAKESPEARE IN LOVE 1998 PORT
MDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union
MDR treatment Shanghai, May 2012 Arnaud Trébucq The Union Why to diagnose MDR-TB? Outcome of SS+ new MDR-TB cases, treated with First Line TB (FLD) drugs Setting Success Died Fail LFFU Transf. Corea 20(56)
CLINICAL USE OF BETA-LACTAMS
CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial
Coccidioidomycosis Nothing to disclose
Coccidioidomycosis Nothing to disclose Disclosure Greg Melcher, M.D. Professor of Clinical Medicine Division of HIV, ID and Global Medicine Zuckerman San Francisco General Hospital University of California,
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
Tuberculosis infection in an Asian elephant at a Japanese Zoo and its first treatment in Japan
Tuberculosis infection in an Asian elephant at a Japanese Zoo and its first treatment in Japan Satoshi Ishikawa, Satomi Suga, Yasuhiko Mukai Fukuyama Zoo, Hiroshima Fukuyama Zoo October 22th, 2017 Tuberculosis
TB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas May 6 9, 2014 MDR/XDR TB Barbara Seaworth, MD May 9, 2014 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial relationships
Tularemia. Information for Health Care Providers. Physicians D Nurses D Laboratory Personnel D Infection Control Practitioners
Tularemia Information for Health Care Providers Physicians D Nurses D Laboratory Personnel D Infection Control Practitioners Tularemia Caused by Francisella tularensis, a small, pleomorphic, gram-negative
Treatment of MDR/XDR-TB. Short course chemotherapy for MDR-TB: practical issues. CHIANG Chen-Yuan MD, MPH, DrPhilos
Treatment of MDR/XDR-TB Short course chemotherapy for MDR-TB: practical issues CHIANG Chen-Yuan MD, MPH, DrPhilos Treatment strategies for MDR-TB Standardized treatment: drug resistance survey data from
Treatment of Multidrug-resistant Tuberculosis (MDR-TB)
Treatment of Multidrug-resistant Tuberculosis (MDR-TB) 2006 2008 2011 2013 2014 2016 2019 Charles L. Daley, MD National Jewish Health University of Colorado Disclosures Research grant Insmed: Phase II
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
M5 MEQs 2016 Session 3: SOB 18/11/16
M5 MEQs 2016 Session 3: SOB 18/11/16 http://tinyurl.com/hn7qzt3 Question 1 Ms Tan is a 52 year old female with no past medical history. She comes to the emergency department presenting with a fever for
TRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 October 2014 GRANUPAS, gastro-resistant granules 30 sachets with a calibrated measuring spoon (CIP: 34009 278 801
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
BRUCELLOSIS BRUCELLOSIS. CPMP/4048/01, rev. 3 1/7 EMEA 2002
BRUCELLOSIS CPMP/4048/01, rev. 3 1/7 General points on treatment Four species are pathogenic to man: B. melitenis (acquired from goats), B. suis (pigs), B. abortus (cattle) and B. canis (dogs). The bacteria
Volume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000.
Volume 8; Number 22 LINCOLNSHIRE GUIDELINES FOR THE TREATMENT OF COMMONLYY OCCURRING INFECTIONS IN PRIMARY CARE: WINTER 2014/15 In this issue of the PACE Bulletin we present an update of our Guidelines
Acute Pyelonephritis POAC Guideline
Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice
1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
Invasive Group A Streptococcus (GAS)
Invasive Group A Streptococcus (GAS) Cause caused by a bacterium commonly found on the skin and in the throat transmitted by direct, indirect or droplet contact with secretions from the nose, and throat
Antibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick
New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick Phillips Patrick.Phillips@ucsf.edu @PPJPhillips Outline Overview of regimen development strategies 1-3 year horizon: Ongoing phase
Antibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
MANAGEMENT OF PELVIC INFLAMMATORY DISEASE
GYNAECOLOGY SERVICES NORTH CUMBRIA MANAGEMENT OF PELVIC INFLAMMATORY DISEASE Author/Contact DOCUMENT CONTROL Lufti Shamsuddin, ST4 Obs & Gynae Trainee / Nalini Munjuluri, Consultant Gynaecology Tel: 01228
Pneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
University of Groningen. Tuberculosis and its sequelae Akkerman, Onno
University of Groningen Tuberculosis and its sequelae Akkerman, Onno IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
CLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
TB New Drugs, Shorter Courses
TB New Drugs, Shorter Courses Brian Chong John Hunter Hospital, Newcastle NSW Talk supervisor: Chris Coulter Disclosures Unfortunately none 1 Current Situation In 2013, Australia had: 1,263 notified TB
SPECIMEN COLLECTION FOR CULTURE OF BACTERIAL PATHOLOGENS QUICK REFERENCE
1 Policy #: Subject: 611 (PLH-611-02) Effective Date: NA Reviewed Date: 2/1/2008 SPECIMEN COLLECTION FOR CULTURE OF BACTERIAL PATHOGENS QUICK REFERENCE Approved by: Laboratory Executive Director, Ed Hughes
Chapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
A man with multiple skin nodules
A man with multiple skin nodules Dr Tommy Tang Infectious Diseases Team Department of Medicine Queen Elizabeth Hospital Part I Bug from afar January 2009 M 42 Married No children no pet Ex-smoker social
Best Journal Articles of 2007 www.snipurl.com/southpaedupdate07 Staying in touch with the literature etoc www.snipurl.com/southpaedupdate07 Best Journal Articles of 2007 Is it interesting? Does it make
DATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only)
Assessment of Appropriateness of ICU Antibiotics (Patient Level Sheet) **Note this is intended for internal purposes only. Please do not return to PQC.** For this assessment, inappropriate antibiotic use
Drug Resistant Tuberculosis:
Drug Resistant Tuberculosis: Pearls and other Considerations John W. Wilson, MD Associate Professor of Medicine Division of Infectious Diseases Mayo Clinic, Rochester MN Mayo Clinic Center for Tuberculosis
Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
Rational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa.
Pneumonia What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa www.netmedicine.com/xray/xr.htm Definition acute infectious disease, etiology usually
Anti-microbial usage and Expectations. Gerald Stokka, DVM, MS Livestock Stewardship
Anti-microbial usage and Expectations Gerald Stokka, DVM, MS Livestock Stewardship WHAT DOES A PULL LOOK LIKE? Signs of Disease Everything is respiratory disease Difficult to distinguish from other conditions
Appropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
Global Status of Antimicrobial Resistance with a Focus on Nepal
Global Status of Antimicrobial Resistance with a Focus on Nepal John Ferguson, John Hunter Hospital, University of Newcastle, NSW, Australia Infectious Diseases Physician and Medical Microbiologist SIMON
Understanding your pet s LIVER CONDITION
Understanding your pet s LIVER CONDITION Why is the liver so important? What causes liver disease in dogs and cats? The liver is one of the largest organs in your pet s body, and it s vital for their good
Critical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary
Running head: ANTIBIOTIC DURATION IN AOM 1 Critical Appraisal Topic Antibiotic Duration in Acute Otitis Media in Children Carissa Schatz, BSN, RN, FNP-s University of Mary 2 Evidence-Based Practice: Critical
Update on diagnosis of feline infectious peritonitis (FIP)
Update on diagnosis of feline infectious peritonitis (FIP) Séverine Tasker RCVS Specialist in Feline Medicine The Feline Centre Langford Veterinary Services University of Bristol http://www.felinecentre.co.uk/
Treatment of Nontuberculous Mycobacterial Infections (NTM)
Treatment of Nontuberculous Mycobacterial Infections (NTM) Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory
Prevention & Management of Infection post Trans Rectal Ultrasound (TRUS) biopsy
Prevention & Management of Infection post Trans Rectal Ultrasound (TRUS) biopsy Dr. Fidelma Fitzpatrick Consultant Microbiologist, Co-chair, NCCP Prostate Bx Infection Project Board Fidelma.fitzpatrick@hse.ie
CDC s Molecular Detection of Drug Resistance (MDDR) Service and Mycobacterium tuberculosis DST Model Performance Evaluation Program (MPEP)
CDC s Molecular Detection of Drug Resistance (MDDR) Service and Mycobacterium tuberculosis DST Model Performance Evaluation Program (MPEP) Beverly Metchock, DrPH, D(ABMM) Mycobacteriology Laboratory Branch/Division
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
Update on Fluoroquinolones. Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO
Update on Fluoroquinolones Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO Potential fluoroquinolone side-effects Increased risk, greater than with most other antibiotics, for
CRANIAL HYDATID CYST
Thi-Qar Medical Journal (TQMJ): Vol(6) No(1):2012(48-52) OBJECT: CRANIAL HYDATID CYST Dr. Haitham Handhal* HYDATID disease is caused by infestation by larvae of the tapeworm Echinococcus granulosus. The
NUMBER: /2005
Purpose PAGE 1 OF 7 The purpose of this policy is to describe the procedures for keeping and maintaining animal medical records. This procedure is approved by the Creighton University Institutional Animal
64 year old retired male (former millwright)
Cheryl Main 2013 None! 64 year old retired male (former millwright) Past medical history Type II Diabetes with Chronic Kidney Disease Sjogren s syndrome treated with plaquenil Autoimmune hemolytic anemia
Quality of 2 nd line medicines for tuberculosis. Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products
Quality of 2 nd line medicines for tuberculosis Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Case studies in medicines for tuberculosis Outline: Statistics
Evaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
Survey of Wisconsin Primary Care Clinicians
... for our health Clinical Approach to Nonresponsive Pneumonia: A Survey of Wisconsin Primary Care Clinicians Hannah A. Louks, 1,3 Jared M. Fixmer, MD 2, and Dennis J. Baumgardner, MD 1,2,3 1 Wisconsin
NEONATAL Point Prevalence Survey. Ward Form
Appendix 2 NEONATAL Point Prevalence Survey Ward Form Please fill in one form for each ward included in PPS Date of survey Person completing form (Auditor code) Hospital Name Department/Ward Neonatal departments
Lyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
Diabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals
Diabetic Foot Infection Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals History of previous amputation [odds ratio (OR)=19.9, P=.01], Peripheral vascular disease (OR=5.5, P=.007)
Second Opinion. Dermatology Service
Second Opinion Dermatology Service Dermatology/Allergy Clinic Veterinary Medical Teaching Hospital University of Wisconsin-Madison SECOND OPINION is an electronic service for referring veterinarians in
NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
NUMBER: R&C-ARF-10.0
1. PURPOSE PAGE 1 OF 6 This policy describes the procedures for keeping and maintaining animal medical records. This procedure is approved by the Creighton University Institutional Animal Care and Use
Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
Considerations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
Multidrug resistant Tuberculosis
Multidrug resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive October 018 Objectives
"What's new in Infectious skin diseases"
"What's new in Infectious skin diseases" Prof. Dr. med. Kathrin Mühlemann Dep. of Infectious Diseases, Inselspital Institute for Infectious Diseases, University of Bern Disclosure Educational Grant with